Clinical Trial Update: Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SB-275833 1% topical ointment versus placebo for impetigo has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impetigo

Drugs mentioned

• SB-275833 ointment (SB-275833)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Impetigo | Phase 3 | Status: COMPLETED